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CD38 is expressed in several types of non-Hodgkin lymphoma and constitutes a promising 
target for antibody-based therapy. Daratumumab (Darzalex) is a first-in-class anti-CD38 
antibody approved for the treatment of relapsed/refractory multiple myeloma. It has also 
demonstrated clinical activity in Waldenström macroglobulinaemia and amyloidosis. Here, we 
have evaluated the activity and mechanism of action of daratumumab in preclinical in vitro 
and in vivo models of mantle cell lymphoma, follicular lymphoma and diffuse large B cell 
lymphoma, as monotherapy or in combination with standard chemo-immunotherapy. In vitro, 
daratumumab engages Fc-mediated cytotoxicity by antibody-dependent cell cytotoxicity and 
antibody-dependent cell phagocytosis in all lymphoma subtypes. In the presence of human 
serum, complement-dependent cell cytotoxicity was marginally engaged. We demonstrated by 
Selective Plane Illumination Microscopy that daratumumab fully penetrated a 3D lymphoma 
organoid and decreased organoid volume. In vivo, daratumumab completely prevents tumor 
outgrowth in models of mantle cell and follicular lymphoma, and shows comparable activity to 
rituximab in a disseminated in vivo model of blastic mantle cell lymphoma. Moreover, 
daratumumab improves overall survival in a mouse model of transformed CD20dim follicular 
lymphoma, where rituximab showed limited activity. Daratumumab potentiates the antitumor 
activity of CHOP and R-CHOP in mantle cell and follicular lymphoma xenografts. Furthermore, 
in a patient-derived diffuse large B cell lymphoma xenograft model, daratumumab anti-tumor 
activity was comparable to R-CHOP and the addition of daratumumab to either CHOP or R-
CHOP led to full tumor regression. In summary, daratumumab constitutes a novel therapeutic 














• Pre-emptive daratumumab completely prevents tumor outgrowth in xenograft models 
of MCL and FL 
• Therapeutic daratumumab improves overall survival in a mouse model of transformed 
CD20dim FL greater than rituximab, and potentiates the antitumor activity of CHOP and 
R-CHOP in MCL and FL xenografts; in a patient-derived DLBCL xenograft model, 
daratumumab activity was comparable to R-CHOP and the addition of daratumumab 


















B cell non-Hodgkin’s lymphoma (NHL) constitutes 4-5% of all hematologic neoplasia with 
increasing incidence in western countries.1 Diffuse large B-cell lymphoma (DLBCL) and follicular 
lymphoma (FL) represent the most frequent aggressive and indolent NHL, accounting for 
approximately 35% and 20 % of all lymphomas, respectively.23 Moreover, roughly one third of 
FL patients develops histologic transformation (tFL) to DLBCL leading to a dismal prognosis.4 
Both entities are currently treated with chemo-immunotherapy including a rituximab 
backbone.5,6 FL responses are usually high, although recurrence occurs in the majority of the 
cases.7 In DLBCL, currently classified into germinal center type (GCB) or activated B-cell type 
(ABC),8 treatment is not guided by subtype, and responses to chemo-immunotherapy are 
normally higher in the GCB subtype. Nevertheless, a portion of DLBCL (20%) do not respond to 
this regimen.9 Several second-generation anti-CD20 antibodies, such as the FDA-approved 
obinutuzumab have been clinically tested to overcome these limitations.10,11 However, an 
alternative evolving therapeutic approach is to target a different antigen. In this regard, both 
FL and DLBCL originate in the germinal center (GC) and consequently express high levels of 
CD38, making this molecule an attractive therapeutic target.12 
Mantle cell lymphoma (MCL) is a rare NHL (6% of all NHL) with an aggressive evolution and 
clinically challenging.13,14 Its frontline therapy, although heterogeneous, typically consists of 
rituximab-based chemo-immunotherapy followed by autologous-stem cell transplantation 
and/or rituximab maintenance. Even with intensive therapy, MCL patients ultimately relapse.15 
Novel targeted therapies currently approved for relapsed/refractory (R/R) MCL include14 the 
mTOR inhibitor temsirolimus, the immunomodulatory agent lenalidomide, the proteasome 
inhibitor bortezomib,
16
 also approved in front-line, and the BTK inhibitor ibrutinib that 
achieves the highest response rates.17 However, MCL patients failing ibrutinib treatment have 
very limited therapeutic options.18 In this situation, where virtually all MCL cases express some 
level of CD38, this antigen represents a potential alternative target to be explored. Moreover, 
CD38 is associated with nodal disease and poorer survival 19,20 and high CD38 expression 
correlates with poor in vivo response to bortezomib21. Thus, targeting CD38 could hold 
promise as a strategy for MCL, also in bortezomib resistant tumors. 
CD38 is present at high levels in bone marrow (BM) precursor cells and it is downregulated in 
resting normal B cells. The molecule is re-expressed at high density once naïve B-lymphocytes 
are activated, and peaks when B cells enter the GC. Terminally differentiated plasma cells and 
their pathological counterparts express the highest surface density among human cells, while 
it is completely absent in memory B cells.22 CD38 behaves simultaneously as an enzyme and as 
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a receptor. The extracellular domain of CD38 contains an enzymatic site that can generate 
cyclic ADP ribose (cADPR) and ADPR from nicotine adenine dinucleotide (NAD+). This control of 
adenosine synthesis by CD38 may be important in the context of the characteristic 
immunosuppressive tumor microenvironment. 
Daratumumab (Darzalex) is a first-in-class, human IgG1ĸ monoclonal antibody that targets the 
CD38 epitope. It was approved by the U.S. FDA in 2015 as a monotherapy for patients with 
multiple myeloma (MM), who have received at least 3 prior therapies.
23
 Currently, 
daratumumab has been approved in combination with dexamethasone plus either 
lenalidomide or bortezomib, or pomalidomide for the treatment of relapsed MM patients.24 
Daratumumab has a broad-spectrum killing activity in MM engaging complement-dependent 
cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC),
25
 antibody-dependent 
cellular phagocytosis (ADCP),26 and apoptosis.27 Moreover, daratumumab modulates the 
enzymatic activity of CD3828 and induces an immunomodulatory role in MM by depleting 
CD38
+
 immune suppressive cells
29
 contributing to its antitumor activity. In chronic lymphocytic 
leukemia (CLL), we have demonstrated that daratumumab induces cytotoxic activity in vitro via 
ADCC and ADCP in primary CLL cells and cell lines. In vivo, Daratumumab significantly prolongs 
overall survival of animals in systemic CLL murine models. Daratumumab also affects tumor-
microenvironment interactions by blocking CLL homing and dissemination to secondary 
lymphoid organs in vitro and in vivo.30  
In the present study, we aimed to investigate in vitro and in vivo activity of daratumumab on 







Daratumumab (Darzalex, anti-CD38mAb, IgG1) and the isotype control mAb (CNTO 3930, IgG1) 
were provided by Janssen. Rituximab (Mabthera, anti-CD20 mAb, IgG1) and the chemotherapy 
regimen CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) were obtained 
from the department of pharmacy of the Hospital Clínic of Barcelona.  
Subcutaneous pre-emptive mouse models 
 SCID mice (Janvier Laboratories) were subcutaneously (sc) injected with 10x106 RL-luc cells in 
the FL model or 10x106 REC-1 cells in the MCL model, respectively, following a protocol 
approved by the Animal Testing Ethic committee of the University of Barcelona and 
Generalitat de Catalunya (Protocol # 9971). Mice were randomly assigned into cohorts of 6 
mice per group and received one intraperitoneal (ip) injection of 10 mg/kg of daratumumab or 
isotype control every other week, starting the day of cell inoculation. 
Patient-derived DLBCL xenograft model 
ST1361 is a DLBCL patient-derived xenograft model developed using a DLBCL tumor originated 
in a metastatic site from a 58-year-old chemotherapy-naïve Hispanic male.  ST1361 was GCB 
subtype transformed from an Epstein-Barr virus negative FL tumor. 
The DLBCL tumor was homogeneously chopped into fragments of similar size and injected sc 
into SCID mice. Treatment was initiated when mean tumor volume was approximately 150-250 
mm
3
.  Daratumumab 20 mg/kg was administered weekly for 3 weeks alone or in combination 
with CHOP (20 mg/kg cyclophosphamide, 1.25 mg/kg doxorubicin, 0.2 mg/kg vincristine 
[intravenously on Day 0], and 0.15 mg/kg prednisone [Days 0-4]; QD for 5 days) or R-CHOP (10 
mg/kg rituximab [intraperitoneally on Day 0]+ CHOP as before).  
Statistical analysis 
Unpaired and paired t-tests were used to assess statistical differences between two groups 
using GraphPad Prism software 4.0. For Kaplan-Meier survival curves, SPSS19 software was 
used. Additional methodologic details are described in Supplementary Methods. 





Daratumumab induces cell killing in the presence of external effectors in B-NHL 
We first assessed by calcein-AM release assay, the ability of daratumumab to induce ADCC, 
ADCP and CDC in MCL, FL and DLBCL cell lines. Using peripheral blood mononuclear cells 
(PBMCs) from healthy donors as external effectors we demonstrated that daratumumab 
engages ADCC in a panel of B-NHL cell lines (Table 1). Daratumumab induced a significant 
dose-dependent cell lysis reaching its maximum antitumor activity at 1 µg/mL on MCL cell lines 
(mean ± SD = 45% ± 14%) (Fig. 1A), at 0.1 µg/mL on FL cell lines (mean ± SD = 48% ± 18%) (Fig. 
1B), and at 0.1µg/mL on DLBCL cell lines (mean ± SD = 49% ± 11%) (Fig. 1C). The degree of 
ADCC induction did not correlate with the number of CD38 molecules per NHL cell (sABC) 
(specific Antibody Binding Capacity) (r2 = 0.1988; Fig. S1A and Table 1). A phagocytosis assay 
using mouse macrophages as effector cells was set up to determine daratumumab-mediated 
ADCP. Daratumumab induced significant ADCP at 1 µg/mL in MCL cell lines (mean ± SD = 54% ± 
24; Fig. 1D) FL cell lines (mean ± SD = 64% ± 26; Fig. 1E), and in DLBCL cell lines (mean ± SD = 
39% ± 18; Fig. 1F). The degree of ADCP induction neither correlated with the number of CD38 
sABC on NHL cell lines (r2 = 0.2270; Fig. S1B and Table 1). 
Interestingly, the daratumumab-opsonized cells that were exposed to macrophages and not 
phagocytosed, suffered a lost in CD38 surface expression, irrespective of the degree of ADCP 
induction (Figure S2), in a process that may resemble trogocytosis as previously described in 
MM studies.31,32 
We next evaluated the CDC activity and observed that, similar to that reported for CLL cells,
30
 
daratumumab induced low to marginal cell death in the presence of normal human serum 
(NHS 10%) (Table 1). Very similar results were obtained in these CDC experiments when 50% 
NHS was applied. The high expression of the complement regulatory proteins (CRPs) CD46, 
CD55 and CD59, and an insufficient number of CD38 molecules per cell on NHL cells may 
explain the low CDC activity (Table 1).  
Collectively, daratumumab effectively kills CD38+ NHL cells through engagement of ADCC and 
ADCP but not CDC, independently of the expression levels of CD38. 
Daratumumab enters and distributes homogeneously within a 3D lymphoma model 
To model the compact aggregates of lymphoma cells growing in the patients’ lymph nodes, 3D 
spheroids were generated by the hanging drop method,33 using RL-GFP cells previously 
reported as an useful tool for antibody therapy studies.34 We first sought to determine the 
degree to which daratumumab can penetrate these lymphoma aggregates depending on dose 
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(1 and 10 µg/mL mAb) and time of exposure (4, 24 and 48 hours). First, we measured the 
percentage of mAb diffusion in the spheroid, representing the total quantity of the mAb in the 
spheroid. Three-dimensional (3D) reconstruction images obtained by SPIM (Fig. 2A) revealed a 
maximum diffusion of daratumumab at 1 µg/mL after 48 hours of treatment (Fig. 2B). Next, 
maximum depth of daratumumab in the spheroids was determined under the same conditions 
and represented as percentage of mAb penetration in the spheroid. As observed for the 
diffusion, a maximum penetration of daratumumab at 1 µg/mL after 48 hours of treatment 
was achieved (Fig. 2C). Moreover, a significant dose-dependent reduction of the spheroid 
volume was observed after daratumumab treatment compared to isotype control (mean ± SD 
= 15% ± 6%, 20% ± 7%, respectively at 1 and 10 µg/mL) (Fig. 2D) showing a direct effect of 
daratumumab on tumor growth in 3D. This observation was validated in additional lymphoma 
cell lines. Daratumumab moderately but significantly (p<0.0001) reduced the spheroid volume 
in all the cell lines analyzed, albeit in a different degree (Fig S3A-B), that was accompanied in 
most of cases by a concomitant decrease in the cell number. However, this observation did not 
apply to HBL-2 and WSU-DLCL2 cell lines, where daratumumab may just generate a tighter 
spheroid (Fig S3C). 
These data demonstrate that daratumumab efficiently penetrates a lymphoma 3D structure 
and moderately reduces the growth of spheroids in the absence of external effectors. 
Daratumumab prevents tumor outgrowth in MCL and FL xenografts 
As a first test of daratumumab activity in vivo in NHL models, we inoculated SCID mice sc with 
two cell lines that we have previously set up, RL cells to model transformed FL (tFL),
35
 and REC-
1 cells to model MCL.36 SCID mice have active NK cells and macrophages that can act as 
effector cells to engage daratumumab activity, as we have shown using in vitro models. Mice 
were treated with daratumumab or isotype control (20 mg/kg) starting on the day of tumor 
injection. Subsequently, animals received antibody injections every other week (10 mg/kg) for 
a total of three doses and were sacrificed at day 30 (REC-1) (Fig. 3A) or day 34 (RL) (Fig. 3B). 
Daratumumab prevented tumor formation in all mice injected with REC-1, and in 5 out of 6 
mice injected with RL cells. In this latter model, a 20mm
3
 RL tumor was found in one 
daratumumab-treated mouse at the endpoint (day 34). As the RL cells inoculated expressed 
the luciferase gene, bioluminescence analysis at different time points further supported these 
results (Fig. 3B). All animals receiving isotype control antibody formed tumors of at least 
100mm
3
 within a mean of 18 days (REC-1) and 21 days (RL) and were bigger than 1000 mm
3
 at 




Daratumumab prolongs overall survival and reduces tumor infiltration in systemic xenograft 
models of MCL and FL  
Next, we generated a model for blastic MCL by inoculating Z-138 cells intravenously into SCID 
mice, and one-week later mice were treated weekly with either daratumumab (D), rituximab 
(R) or isotype (I) control (20/10/10/10 mg/kg). Seven out of ten isotype-treated mice had to be 
sacrificed between days 57 - 89 due to systemic signs of disease (Fig. 4). Daratumumab 
significantly improved overall survival (OS) (I vs D: ***p< 0.001), with 90% of the mice treated 
with daratumumab surviving for over 107 days, (Fig. 4A) compared to just 10 % alive in the 
controls. OS for the daratumumab group was slightly superior but did not reach statistical 
significance (D vs R: ns p = 0.2907), compared to that observed in the rituximab-treated mice (I 
vs R: **p<0.01), where 70% of the mice were alive at day 107 (Fig. 4). Mean survival was 73 
days for the control group, 97 for rituximab and 103 for daratumumab groups. On autopsy, the 
disease had spread to brain, BM, spleen and lungs (Fig. S4A). Daratumumab treatment 
reduced the disease burden in brain, BM, and spleen by 93%, 63%, and 48%, respectively (Fig 
S4B). Rituximab-treated mice showed a similar reduction in tumor load to that achieved by 
daratumumab in brain (73%) and BM (69%) compared to that observed with the isotype 
control, while no effect was observed in spleen infiltration. Finally, daratumumab did not 
diminish lung infiltration, while a moderate reduction was seen in rituximab-treated mice 
(18%) compared to isotype control mice (Fig. S4B), suggesting organ-dependent differential 
immunotherapeutic response. 
In the FL systemic model, CD20low WSU-FSCCL cells (Table 1) were intravenously inoculated in 
SCID mice and one-week later mice were treated weekly with daratumumab, rituximab or 
isotype control (20/10/10/10 mg/kg). All control-treated and rituximab-treated mice rapidly 
succumbed to the disease and died or had to be euthanized due to severe disease signs by day 
40 (control group) and day 62 (rituximab group), respectively (Fig. 4). In contrast, in the 
daratumumab-treated group, OS was significantly prolonged (I vs D: ***p< 0.001 I vs R: 
**p<0.01; D vs R *p< 0.05). Mean survival was 35 days for the control group, 41 for rituximab 
and 60 for daratumumab. By the end of the experiment (day 90), 30% of mice treated with 
daratumumab were cured (Fig. 4). On autopsy, WSU-FSCCL cells showed systemic 
dissemination of disease in brain, BM and spleen (identified as huCD45+/CD19+/CD10+; Fig. 
S4C). Daratumumab robustly decreased dissemination to brain (90%, p< 0.01) as compared to 
the control group, while rituximab was not effective (Fig. S4D). Homing of WSU-FSCCL cells to 
the spleen and BM was less prominent. There were no significant differences in the reduction 
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of dissemination to spleen and BM by daratumumab compared to the rituximab-treated group 
(Fig. S4D). 
Altogether, these data confirm that daratumumab shows comparable to superior activity with 
respect to rituximab in systemic models of MCL and FL  
Daratumumab synergizes with R-CHOP to reduce tumor burden in preclinical models of MCL 
and FL 
The synergy between daratumumab and rituximab and/or chemotherapy regimens was 
evaluated in MCL (REC-1) and tFL (RL) xenograft heterotopic models. SCID mice were 
inoculated subcutaneously with NHL cells and when tumors became palpable, mice were 
randomly assigned into the following groups: i) Isotype ii) daratumumab iii) CHOP iv) D-CHOP 
v) R-CHOP and vi) R-D-CHOP. Tumor volume was assessed twice a week and tumor weights at 
sacrifice. In the MCL model (Fig. 5A), daratumumab induced significant anti-tumor activity 
compared to the isotype control (42%, p< 0.01). CHOP alone marginally reduce tumor growth 
(p = 0.182) and no difference was observed between daratumumab and D-CHOP groups (p = 
0.451). Importantly, adding rituximab to D-CHOP treatment (R-D-CHOP) induced a significant 
reduction in tumor volume compared to the isotype control (86%, p< 0.001) and also 
compared to R-CHOP (73% p < 0.001) and D-CHOP (51%, p < 0.05) alone. Similarly, in the tFL 
model (Fig. 5C-D), daratumumab treatment inhibited tumor growth compared to isotype 
control (36%, p< 0.001). On the other hand, the combination D-CHOP inhibited tumor growth 
significantly better than daratumumab as a single agent (57%, p< 0.001), resembling that 
achieved by R-CHOP (67%, p< 0.001). In addition, the combination regimen of R-D-CHOP had a 
remarkable effect in impeding tumor growth (84% inhibition, P< 0.001), which was superior 
than that achieved by each combination regimen separately (p< 0.001). The results of the RL-
luc model were further validated by bioluminescence and quantification of the signal captured 
at the endpoint (Fig. S5A-B). Moreover, tissue sections of selected mice of each group were 
analyzed by immunohistochemistry for the proliferation marker pH3 and the angiogenesis 
marker CD31, further confirming these results (Fig. S5C). 
In conclusion, these data demonstrate the value of the combination R-D-CHOP as a new 
therapeutic strategy in MCL and tFL superior to the standard of care (R-CHOP) 
Daratumumab induces tumor growth inhibition and prolongs survival in a patient-derived 
DLBCL xenograft model in combination with R-CHOP 
To further evaluate the activity of daratumumab alone or in combination with the standard-of-
care therapy we used a clinically more relevant patient-derived DLBCL xenograft model 
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(ST1361) with detectable CD38 expression by immunohistochemistry (Fig S6). Identical to the 
MCL and tFL models, all individual treatments were capable of reducing tumor volume over 
time (p<0.001, Fig 6A); however, daratumumab alone was strikingly efficient with an anti-
tumor activity comparable to R-CHOP (p<0.001, Fig 6A). Furthermore, the addition of 
daratumumab to either CHOP or R-CHOP led to full tumor regression (p<0.001, Fig 6A). 
Importantly, tumor volume negatively correlated very well with the OS of xenograft-bearing 
mice, regardless the treatment group (Fig 6B). Thus, mice treated with either daratumumab 
alone or R-CHOP displayed identical OS and, in line with the full tumor regression achieved, 
daratumumab combined with either CHOP or R-CHOP resulted in 100% survival at the end of 
the experiment (p<0.05 after Bonferroni multiplicity correction, Fig 6A).  Remarkably, full 
tumor regression and 100% a survival at day 60 were observed even when daratumumab 
treatment was ceased as early as 14 days (total of 3 doses) after tumor cell inoculation. 
Collectively, these results indicate that tumor cells were completely eliminated within a short 
time and that no tumor escape occurred in this DLBCL patient-derived model.  
 
DISCUSSION 
In this study we have demonstrated that daratumumab engages Fc-mediated cell killing of NHL 
cells by ADCC and ADCP. Variation in the extent of ADCC and ADCP could not be explained by 
the differences in CD38 expression levels. Similar observations were also reported for 
daratumumab-induced ADCC and ADCP in CLL cells.30 The capacity of daratumumab to induce 
ADCC and phagocytosis may to some extent be related to other factors, such as the expression 
of different types of FcγR, KIRs and Natural Cytotoxic Receptors (NCR) on NK cells.37 Moreover, 
the expression of the so-called ‘don’t eat me’ signals, such as CD47, on tumor cells plays an 
important role in regulating phagocytosis. In fact, CD47 expression has been found to be 
increased on MCL, FL and DLBCL cells compared to normal cells, conferring a worse clinical 
prognosis.
38
 Moreover, in agreement with previous results in MM, 
32
 the daratumumab-
opsonized cells that were exposed to macrophages and not phagocytosed, suffered a lost in 
CD38 surface expression. This event may reduce the ability of daratumumab to kill lymphoma 
cells via CDC and ADCC, compromising the therapeutic efficacy of daratumumab. However, 
MM studies demonstrated that this phenomenon occurs early in the treatment irrespective of 
their clinical responses.32 Therefore, CD38 reduction via trogocytosis should not necessarily be 
considered as an escape mechanism from daratumumab treatment. On the contrary, 
trogocytosis may be beneficial and represent a novel mechanism of action of daratumumab, as 
in this process there is also transfer of tumor cell membrane fragments containing important 
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signaling molecules such as CD56 CD49d and CD138. The decreased expression of these 
adhesion molecules in tumor cells may compromise their interaction with tumor 
microenvironment as we reported in a previous work. 30 
Daratumumab did not induce CDC in FL, or DLBCL or MCL cell lines. Flow cytometry analysis 
demonstrated that MCL and FL cells show medium to high expression of CD38 while DLBCL 
cells tend to express higher levels of CD38. However, the number of molecules per cell in these 
NHL cell lines was lower than that found on the CDC-sensitive Daudi Burkitt lymphoma cell 
line, suggesting a threshold for CD38-targeted CDC lysis. In addition, this low induction of CDC 
was also associated with high expression of the CRPs CD55 and CD59 that were lower in Daudi 
cells. These observations are in line with our previous data obtained for CLL cell lines and 
primary cells.
30
 Overall, baseline expression of CD38/CD55/CD59 appears to be associated with 
response to daratumumab-induced CDC in vitro in FL, DLBCL and MCL cells. These results 
mirrored those obtain with the anti-CD20 rituximab in CLL cells.39 
We have shown for the first time that daratumumab, at clinically achievable doses, effectively 
penetrates a lymphoma organoid in vitro model. A moderate but significant reduction of the 
sphere volume was observed with daratumumab in 3D models of lymphoma, even though no 
significant effect was observed in a 2D model (data not shown). These results agree with 
daratumumab efficacy against subcutaneous tumors in vivo (Figs 5 and 6). 
In vivo results support the ability of daratumumab to prevent the outgrowth of MCL and FL 
cells, when administered in a prophylactic setting, prior to tumor development. These results 
open a window of opportunity for daratumumab as an alternative to rituximab maintenance 
therapy in these models, in the context of a complete response after the induction therapy.40,41 
Moreover, we have demonstrated that daratumumab shows single agent activity both in 
systemic and subcutaneous models of NHL, when administered after disease onset. More 
importantly, the data from the FL model using WSU-FSCCL cells point to a possible role for 
daratumumab as a therapeutic alternative to rituximab in NHLs with reduced CD20 expression. 
Previous studies have shown a substantial and rapid reduction of CD20 in lymphoma patients 
treated with rituximab, which has been linked to development of acquired resistance.
42,43
 
Thus, daratumumab treatment may be considered in these scenarios where anti-CD20 
resistance has developed due to antigen shaving.44 In addition, our results indicate that 
daratumumab significantly improves long-term survival when used as a single agent, indicating 
that it may be also an alternative to rituximab in NHL CD20
high
, evidenced by the comparable 
activity of both antibodies in the blastic MCL model using Z-138 cells.  We have also observed a 
remarkable effect of daratumumab in the tumor cell dissemination to brain in FL and MCL 
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systemic models. This may be related to the capacity of daratumumab to cross the hemato-
encephalic barrier. In fact, daratumumab has shown efficacy in CNS plasmocytoma45 and 
extramedullary myeloma.46  
Finally, we have examined the combination of daratumumab with the standard of care therapy 
R-CHOP. Our data suggest that daratumumab significantly potentiates R-CHOP activity, 
inducing higher rates of tumor regression in MCL and FL. Moreover, we analyzed the efficacy 
of daratumumab in a DLBCL patient derived mouse xenograft, generated from a transformed 
FL, and usually less responsive to chemotherapy, as shown in our results where indeed the 
CHOP regimen displayed limited activity. In this model, daratumumab in combination just with 
CHOP, in the absence of rituximab leads to completely abrogation of tumor growth. This 
strong synergy may be explained by the induction of stress-related cytokines by 
chemotherapeutic agents that can effectively target cancer cells for removal by the innate 
immune system through macrophage infiltration and phagocytic activity,47 potentially 
augmenting the described ability of daratumumab to engage ADCP.
26
 
In the phase II clinical trial CARINA, LYM2001 in R/R NHL, daratumumab monotherapy did not 
yield the expected results in heavily pretreated FL and DLBCL patients, while no results could 
be concluded in MCL because of insufficient patient recruitment. However, we have identified 
certain NHL scenarios were daratumumab shows comparable antitumor activity as rituximab 
(blastic MCL) and other where exhibits superiority (transformed CD20dim FL). Moreover, 
daratumumab potentiates the antitumor activity of CHOP and R-CHOP in all three models.  
In addition, as demonstrated in MM, it is likely that daratumumab may modulate the activity 
and frequency of CD38 expressing immune suppressive cell populations present in NHL, an 
effect not exerted by rituximab, and therefore may offer a superior overall antitumor effect. 
29
 
These may be of special relevance in FL and DLBCL where infiltration of diverse T and myeloid 
subpopulations is specially prominent.48 The immune-compromised mouse models used in this 
study preclude the analysis of this immune-modulating activity of daratumumab.  
In conclusion, our findings warrant further clinical development of daratumumab in NHL 
providing a strong rationale for examining its clinical efficacy in different scenarios, including 
maintenance therapy after induction therapy, cases with anti-CD20 resistance, FL histologic 
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1 %CD551 %CD591 %ADCC4 %ADCP4 %CDC4 
Jeko MCL 16253 84 22 100 46 92 98 61 58 41 7 
REC-1 MCL 106234 100 155 100 77 99 99 88 60 46 18 
HBL2 MCL 25317 100 92 100 99 98 96 98 28 21 0 
Mino MCL 127458 100 51 100 42 97 100 96 32 35 0 
UPN1 MCL 54089 99 97 97 8 98 99 63 36 73 0 
Z138 MCL 186239 100 120 100 28 100 75 69 53 89 0 
DOHH2 FL 22369 87 20 99 31 100 76 98 25 38 0 
SC-1 FL 71726 100 40 32 4 95 96 83 41 81 1 
RL FL 132684 96 76 93 49 100 94 97 52 45 6 
WSU-FSCCL FL 89707 97 354 8 2 82 81 94 67 92 7 
Toledo DLBCL 123539 99 186 89 13 94 99 97 34 50 14 
WSU-DLCL2 DLBCL 14926 94 46 99 137 95 95 98 45 15 1 
SU-DHL-6 DLBCL 174033 92 383 98 172 97 44 31 64 56 5 
SU-DHL-4 DLBCL 96623 96 108 100 45 93 45 95 61 34 8 





Figure 1. Daratumumab induces ADCC and ADCP in the presence of external effectors in NHL. 
(A) MCL, (B) FL, and (C) DLBCL cell lines were treated with increasing DARA doses (0.0001-1 
µg/mL) in the presence of PBMCs from healthy donors at a E:T ratio of 50:1 for 4 hours. 
Viability was then evaluated by calcein release assay. The BL cell line, Daudi, was included as 
positive control. (D) MCL, (E) FL, and (F) DLBCL cell lines were labeled with calcein and 
incubated for 4h with the mΦ at an E:T ratio of 1:1 in the presence of a fixed DARA 
concentration of 1 μg/mL, followed by flow cytometry analysis in triplicates. ADCP was 






 cells after DARA treatment referred to 
isotype-treated cells. Daudi cells were included as positive control. 
Figure 2. Daratumumab effect in a 3D model of FL. 
3D spheroids of RL-GFP cells were obtained after 3 days of culture in hanging drop plates or 
96-well ultra-low attachment plates, and then treated with 10 µg/mL of Isotype control (IgG1), 
or 1 or 10 µg/mL of DARA at different times. (A) 3D reconstruction images produced by SPIM; 
fluorescence was measured at a λex of 488nm (GFP) and 561nm (mAbs labeling). (B) 
Percentage of mAb diffusion, representing quantity of the mAb in the spheroid. (C) Percentage 
of mAb penetration, representing maximum depth of the mAb in the spheroid. (D) Spheroid 
volume (mm
3
) time course (n = number of spheroids per treatment). Statistical differences 
between groups were assessed by unpaired t-test (**, p < 0.01; ***, p < 0.001). 
Figure 3. Daratumumab efficacy in pre-emptive models of MCL and tFL. 10x106 REC-1 cells (A) 
or RL-luc cells (B) were mixed with matrigel (1:1) and subcutaneously injected in SCID mice (n = 
6 per group). Animals received one dose every other week (10 mg/kg of isotype control (IgG1) 
or DARA) starting the day of cell inoculation. Tumor growth curves over time clearly show total 
regression was achieved in both models. As RL cell line expressed the luciferase gene, 
sequential bioluminescence images were captured at different time points (B). Statistical 
differences between groups were assessed by unpaired t-test (***, p < 0.001). 
Figure 4. Daratumumab monotherapy in a systemic model of MCL and FL compared to 
rituximab. 10x10
6
 Z-138 (MCL) and WSU-FSCCL (FL) cells were intravenously injected in SCID 
mice (n = 10 per group). Treatment (isotype control (IgG1)/ Daratumumab/ Rituximab) started 
one week after inoculation and went on weekly for 4 weeks (20/10/10/10 mg/kg), as indicated 
by the red arrows. Mice were monitored twice weekly for any sign of disease and were 
euthanized when body weight decreased 15-20%. Survival curves are represented. Statistical 
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differences between groups were assessed by log-rank test. Z-138 : Overall significance***p < 
0.001; Isotype; Ctrl vs DARA ***p < 0.01; DARA vs Rituximab ns p=0.2907. WSU-FSCCL: Overall 
significance ***p < 0.001; Isotype Ctrl vs Dara ***p ≤ 0.001; Dara vs Rituximab  *p=0.045.  
Figure 5. Daratumumab combined with R-CHOP in MCL and tFL. 10x10
6
 REC-1 (A-B) and RL-luc 
(C-D) cells were mixed with matrigel (1:1) and subcutaneously injected in SCID mice (REC-1: 
n=5-7 per group; RL: n 7-10 per group). Treatment as monotherapy (isotype control (IgG1)/ 
DARA/ RITUX/ CHOP) or the combination regimen DARA ± RITUX ± CHOP started one week 
after inoculation and went on weekly during 3 weeks for the mAbs (20/10/10 mg/kg) in REC 
model, and 4 weeks (20/10/10/10 mg/kg) for RL model.  CHOP was given as an initial unique 
dose the first day of treatment in both models. Tumor growth curves over time are 
represented for each cohort (A and C). Tumor weight for each treatment was averaged and 
represented at endpoint for REC-1 (B) and RL models (D). Statistical differences between 
groups were assessed by unpaired t-test (**, p < 0.01; ***, p < 0.001). 
Figure 6. Daratumumab combined with R-CHOP in a patient-derived DLBCL xenograft model. 
Fragments from a patient-derived DLBCL were injected subcutaneously into SCID mice (n = 8-
10) and staged to approximately 150 to 250 mm3 mean tumor volume to measure (A) tumor 
growth and (B) OS.  20 mg/kg daratumumab was administered weekly alone or in combination 
with CHOP (20 mg/kg cyclophosphamide, 1.25 mg/kg doxorubicin, 0.2 mg/kg vincristine, and 














and	 DLBCL	 cell	 lines	 SU-DHL-4	 and	 SU-DHL-6	 were	 obtained	 from	 DSMZ	 (Braunschweig,	
Germany).	 MCL	 cell	 lines	 Jeko-1,	 Mino,	 REC-1,	 Z-138	 and	 DLBCL	 cell	 line	 WSU-DLCL2	 were	
obtained	 from	ATCC	 (LGC	Standards,	Teddington,	UK).	HBL-2	was	kindly	provided	by	Prof.	M	
Dreyling	(University Hospital, Munich, Germany),	UPN-1	by	Dr.	A	Turhan	(Hôpital Bicêtre et Paul 
Brousse, Villejuif, France) and	Toledo	cell	line	by	Dr.	MA	Piris	(Fundación	Jiménez	Díaz,	Madrid,	
Spain).	The	RL	cell	line	expressing	luciferase	(RL-luc)	was	generated	via	retroviral	transduction.	
Retroviral	 vectors	 containing	 full-length	 pLHCX-luc	were	 kindly	 provided	by	Dr.	 Bofill-De	Ros	
(IDIBAPS,	 Barcelona,	 Spain)	 (see	 below	method	 description).	 RL-GFP	 cells	were	 produced	 by	
the	 Inserm	 UMR1037	 vector	 facility	 (CRCT,	 Toulouse,	 France)	 and	provided	 by	 JJ	 Fournié's	
laboratory	 (CRCT).	 Cell	 lines	 were	 cultured	 in	 RPMI-1640	 supplemented	 with	 10%	 FBS,	 2	
mmol/L	 L-glutamine,	 50	 µg/mL	 penicillin/streptomycin	 (Life	 Technologies)	 and	 were	
maintained	 in	 a	 humidified	 atmosphere	 at	 37ºC	 containing	 5%	 CO2.	 Normocin	 (100	 µg/mL;	




Supernatant	 of	 Phoenix	 cells	 containing	 retroviral	 particles	 was	 used	 to	 infect	 RL	 cells	 by	





ADCC	was	 performed	 using	 a	 calcein-release	 assay	 as	 described	 previously	 (30).	 Target	 cells	
were	 exposed	 to	 10-fold	 serial	 dilutions	 of	 either	 isotype	 control	 (CNTO	 3930,	 spontaneous	
release)	or	daratumumab	(range,	1	to	0.0001	µg/mL)	in	RPMI-1640	in	the	presence	of	healthy	
donor	 PBMC	 at	 E:T	 ratio	 of	 50:1	 for	 4	 hours.	 10%	 Triton	 was	 used	 to	 determine	 maximal	
release.	The	percentage	of	cellular	cytotoxicity	was	calculated	using	the	following	formula:	
% 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑙𝑦𝑠𝑖𝑠 = 100×
𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 𝑅𝐹𝑈 – 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 (𝑅𝐹𝑈)





hind	 legs	 of	 female	 SCID	mice	 (C.B-17/Icr-Prkdcscid/Crl;	 Janvier	 Labs),	 by	 flushing	 the	 femurs.	
The	cells	were	cultured	for	7	days	in	DMEM	supplemented	with	10%	FBS,	2	mM	L-glutamine,	
50	µg/mL	penicillin/streptomycin,	and	50	U/ml	M-CSF	(Cell	Guidance),	and	the	culture	medium	
was	 renewed	 every	 3	 days.	 On	 day	 7,	 mφ	 were	 detached	 with	 0.1%	 trypsin-EDTA	 and	





After	 4hr	 of	 incubation,	 the	 non-phagocytosed	 target	 cells	 were	 collected.The	 mφ	 were	
detached	with	0.1%	trypsin-EDTA,	added	to	the	non-phagocytosed	target	cells	and	stained	for	
F4/80	expression.The	amount	of	remaining	target	cells	(CD19+	calcein+	F4/80-)	was	determined	
on	 an	 Attune	 acoustic	 cytometer.	 	 The	 percentage	 of	 killed	 target	 cells	 in	 the	 presence	 of	
daratumumab	compared	with	isotype	control	was	calculated	using	the	following	formula:	
% 𝐴𝐷𝐶𝑃 = 100 − [100×
𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝑡𝑎𝑟𝑔𝑒𝑡 𝑐𝑒𝑙𝑙𝑠 𝑎𝑓𝑡𝑒𝑟 𝐷𝐴𝑅𝐴 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝑡𝑎𝑟𝑔𝑒𝑡 𝑐𝑒𝑙𝑙𝑠  𝑎𝑓𝑡𝑒𝑟 𝑖𝑠𝑜𝑡𝑦𝑝𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
]	
Complement-dependent	cytotoxicity	
Target	 cells	 were	 labeled	 with	 1	 μM	 Calcein-AM	 (Life	 Technologies)	 for	 30	 min	 at	 37ºC.	
Afterwards,	cells	were	washed	thrice	with	PBS,	plated	in	triplicate	at	1×105	cells/well	in	96-well	
round	bottom	plates,	 and	preincubated	 (room	 temperature	 {RT},	 15	min)	with	10-fold	 serial	
dilutions	 of	 either	 isotype	 control	 (CNTO	 3930)	 or	 DARA	 (range:	 10	 to	 0.01	 μg/mL)	 in	 RPMI	
1640.	 Culture	 medium	 was	 added	 instead	 of	 mAb	 to	 determine	 the	 spontaneous	 calcein	
release	and	1%	Triton	X-100	was	used	to	determine	the	maximal	calcein	release.	Thereafter,	
10%	normal	human	AB	serum	was	added	and	 incubated	for	45	min	at	37°C.	The	plates	were	





% 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑙𝑦𝑠𝑖𝑠 = 100×
𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 𝑅𝐹𝑈 – 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 (𝑅𝐹𝑈)







GFP	 cells	 (2.5x105	 cells/mL)	 were	 prepared	 in	 complete	 medium	 containing	 1%	 Methocult	






% 𝑝𝑒𝑛𝑒𝑡𝑟𝑎𝑡𝑖𝑜𝑛  = 100 ×
𝐺𝑙𝑜𝑏𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 561 𝑛𝑚
𝑅𝑒𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 488 𝑛𝑚
	
% 𝑑𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛  = 100 ×
𝑅𝑒𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 561 𝑛𝑚






×𝜋 × 𝐿 𝑙𝑜𝑛𝑔𝑒𝑠𝑡 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟  × 𝑙!(𝑠ℎ𝑜𝑟𝑡𝑒𝑠𝑡 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟)	
CD38	molecules	per	cell	quantification	
FL	and	MCL	cell	lines	were	stained	with	QuantiBRITE™	CD38-PE	(BD	Biosciences)	and	the	mean	




SCID	mice	were	 intravenously	 (iv)	 injected	with	10x106	WSU-FSCCL	 (FL)	or	Z-138	cells	 (MCL),	
following	approval	of	the	protocol	by	the	Animal	Testing	Ethic	committee	of	the	University	of	
Barcelona	 and	 Generalitat	 de	 Catalunya	 (Protocol	 #	 9971).	 One	 week	 later,	 mice	 were	
randomly	 assigned	 into	 cohorts	 of	 10	 mice	 per	 group	 and	 received	 one	 intraperitoneal	







through	 70	µm	nylon	 sieves	 (BD	 Falcon).	 Erythrocytes	were	 lysed	 using	 ACK	 buffer	 (Quality	





REC-1	 cells	 in	 the	MCL	 model.	 Mice	 were	 randomly	 assigned	 into	 cohorts	 of	 6-8	 mice	 and	
treated	once	a	week	 ip	with	 the	 isotype	 control,	 daratumumab,	or	 rituximab,	 starting	when	
tumors	 were	 palpable	 (day	 7)	 following	 the	 schedule	 (20/10/10	 mg/kg	 in	 REC-1	 and	
20/10/10/10	mg/kg	in	RL-luc).	The	chemotherapy	regimen	CHOP	was	given	as	an	initial	single	
dose	with	 the	 first	 dose	 of	 antibodies	 (cyclophosphamide:	 25mg/kg;	 doxorubicin:	 2.5mg/kg;	
vincristine:	 0.4mg/kg	prednisone:	 0.15mg/kg).	 Tumor	 volume	was	measured	 twice	per	week	
with	external	calipers	and	calculated	using	the	standard	formula:	𝑠! × 𝑙 × 0.5,	where	(𝑠)	is	the	
shortest	diameter	of	the	tumor	and	(𝑙)	the	longest.	As	the	RL	cell	line	expressed	the	luciferase	
gene,	sequential	bioluminescence	 images	were	captured	after	 injecting	150	mg/kg	XenoLight	
D-Luciferin	 (Perkin	 Elmer),	 and	 measured	 radiance	 by	 Wasabi	 software	 (Hamamatsu	
Photonics).	Animals	were	sacrificed	after	one	month	according	to	institutional	guidelines,	and	
tumors	 were	 collected	 and	 weighed.	 Tumor	 samples	 were	 formalin-fixed	 and	 embedded	 in	







Figure	 S1.	 Correlation	 between	 the	 number	 of	 CD38	 molecules	 per	 cell	 and	 effector	
mediated	 cell	 death.	 Number	 of	 surface	 antibodies	 bound	 per	 cell	 (sABC)	 of	 CD38	 was	
quantified	in	MCL,	FL	and	DLBCL	cell	lines,	including	Daudi	as	a	positive	control,	and	plotted	for	
correlation	 with	 (A)	 ADCC	 and	 (B)	 ADCP	 induction	 by	 DARA	 at	 0.1	 µg/mL	 and	 1	 µg/mL,	
respectively.	Statistical	significance	was	assessed	by	Spearman	test.	
Figure	 S2.	 Daratumumab	 decreases	 CD38	 surface	 expression	 in	 the	 presence	 of	
macrophages.	ADCP	was	performed	in	representative	MCL,	FL	and	DLBCL	cell	lines.	At	the	end	




FL	 and	 DLBCL	 cells	 lines	 were	 seeded	 on	 ultra-low	 attachment	 plates	 (ULA)	 at	 day	 0	 and	
daratumumab	(10µg/mL)	was	added	at	3	day	for	48hr.		Images	were	captured	in	a	Cytation	1	





×𝜋 × 𝐿 𝑙𝑜𝑛𝑔𝑒𝑠𝑡 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟  × 𝑙! 𝑠ℎ𝑜𝑟𝑡𝑒𝑠𝑡 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 	
Afterwards,	 these	 spheroids	 were	 manually	 disaggregated	 and	 cell	 count	 was	 evaluated	 by	
flow	cytometry	(C).	
Figure	S4.	Tumor	infiltration	in	systemic	xenograft	models	of	FL	and	MCL.		(A-B)	Tumor	cells	
infiltrating	 the	 brain,	 BM,	 spleen	 and	 lungs	 from	 the	 Z138	 model	 were	 recovered	 at	 the	
endpoint,	stained	with	huCD45/CD19	and	counted	by	flow	cytometry.	Representative	density	
plots	 for	 one	 mouse	 of	 each	 cohort	 are	 shown.	 (C	 and	 D)	 Total	 number	 of	
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